Research | Core Facilities | Patient Studies | Tech Transfer | Seminars | Intranet | Jobs | Search | Contact Us | Ways To Give HOME
|
|
|
|
|
|
|||
|
Research | Core Facilities | Patient Studies | Tech Transfer | Seminars | Intranet | Jobs | Search | Contact Us | Ways To Give HOME |
|||
 |
|||
|
RA Studies Studies in which participants receive new (investigational) treatments: IMPRESS
(Genentech) - Protocol U3900s: The main goal of this study looks at the
joints with the use of MRI for evidence of erosions and joint destruction of
patients receiving rituximab compared to patients receiving placebo
(inactive drug). CENTOCOR
(Centocor) - Protocol C0524T12: This study investigates the
experimental drug called golimumab in combination with either methotrexate
or placebo (inactive methotrexate) for treatment of RA. If you participate
in this research study, you will receive either the study medication or a
placebo (inactive drug). SCRIPT
(Genentech) - Protocol WA20495/ACT3986g: This study investigates
the experimental drug called ocrelizumab in combination with either
methotrexate or Arava (leflunomide) for the treatment of RA in patients who
have tried one of the new biologics (Enbrel, Humira, Remicaide) in the past.
If you participate in this research study, you will receive either the study
medication of a placebo (inactive drug). FILM
(Genentech) - Protocol WA20497/ACT3984g: This study is to determine
the efficacy of ocrelizumab versus placebo when used in combination with
MTX to reduce or slow down the progression of joint damage. SUNDIAL
(Genentech) - Protocol U3924g: This study further investigates the
drug rituximab when used in combination with another DMARD
(disease-modifying anti-rheumatic drug). If you participate in this
research study, you will receive rituximab (study drug); there is no
placebo (inactive drug). IMAGE
(Genentech) -
Protocol WA17047/U3373g: A randomized, phase 3 controlled, double blind, parallel group, multicenter
study to evaluate the safety and efficacy of Rituximab in combination with Methotrexate (MTX) compared
to MTX alone, in Methotrexate-naive patients with active rheumatoid arthritis. (sponsored by Genentech) SERENE
(Genentech) - This
is a research study of an investigational product called rituximab (MabThera
â/Rituxan
â). Rituximab is a monoclonal
antibody that has been approved for the treatment of non-Hodgkin’s B cell lymphoma (a type of
cancer) by the Food and Drug Administration (FDA) but has not been approved for the treatment of
rheumatoid arthritis. (sponsored by Genentech) IM101-31 #03-02 - The purpose of the
long-term extension phase is to evaluate the safety (possible side effects) and long term use of
Abatacept in the treatment of rheumatoid arthritis.
Studies that involve blood drawing, medical history, and physical examinations: no changes in medicines Oklahoma Rheumatoid
Arthritis Cohort (ORAC) - This project is a study of a group of
patients with rheumatoid arthritis (RA) . This study has three main goals:
1) to evaluate more sensitive techniques to look at joints of people with RA
as a possible method to improve the selection and evaluation of treatments.
This technique is called magnetic resonance imaging (MRI). MRI does not use
x-rays to take a picture of the joint. It uses a magnetic field, which makes
the image by causing small molecules to align in the magnetic field. The MRI
takes a 3 dimensional picture. It provides the doctor with a more clear,
better picture; 2) to study the causes of RA, its progression and
complications (such as heart disease, strokes, and the side effects of
medications and relate this to MRI evidence of inflammatory activity; 3) to
examine the justification for possible new treatments for RA by studying
blood samples and relating this to clinical problems and MRI. This study
will not affect your medications or medical care. You will have your health
history, a physical examination and blood donation every 3 months. You will
have an MRI done every 6 months. This study is expected to continue for a
minimum of 15 years and will include up to 500 patients and up to 50
controls (healthy individuals and patients with another rheumatologic
disease) from a wide region around Oklahoma City.
Return to Table of Contents Clinical Pharmacology Research Program
|
|||